Evidence map›Paper›PMID 25454821›Full record

Trial reportMolecular oncology2015

PHF21B as a candidate tumor suppressor gene in head and neck squamous cell carcinomas.

Fernanda Bernardi Bertonha, Mateus de Camargo Barros Filho, Hellen Kuasne, Patricia Pintor Dos Reis, Erika da Costa Prando, Juan José Augusto Moyano Muñoz, Martín Roffé, Glaucia Noeli Maroso Hajj, Luiz Paulo Kowalski, Claudia Aparecida Rainho and 1 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Familial Cancers of Head and Neck Region.Journal of clinical and diagnostic research : JCDR · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fernanda Bernardi BertonhaInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: bertonhafb@gmail.com.
Mateus de Camargo Barros FilhoInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: mateuscbarros@gmail.com.
Hellen KuasneInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: khellenk@gmail.com.
Patricia Pintor Dos ReisDepartment of Surgery and Orthopedics, Faculty of Medicine, UNESP - Sao Paulo State University, Botucatu, SP 18.618-970, Brazil. Electronic address: preis@fmb.unesp.br.
Erika da Costa PrandoDepartment of Genetics, Institute of Biosciences, UNESP - Sao Paulo State University, Botucatu, SP 18.618-970, Brazil. Electronic address: erikaprando@gmail.com.
Juan José Augusto Moyano MuñozInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: juanjomoy@gmail.com.
Martín RofféInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: mroffe@cipe.accamargo.org.br.
Glaucia Noeli Maroso HajjInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil. Electronic address: ghajj@cipe.accamargo.org.br.
Luiz Paulo KowalskiDepartment of Head and Neck Surgery and Otorhinolaryngology, A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil; National Institute of Science and Technology in Oncogenomics (INCITO), Sao Paulo, SP 01.509-010, Brazil. Electronic address: lp_kowalski@uol.com.br.
Claudia Aparecida RainhoDepartment of Genetics, Institute of Biosciences, UNESP - Sao Paulo State University, Botucatu, SP 18.618-970, Brazil. Electronic address: rainho@ibb.unesp.br.
Silvia Regina RogattoInternational Center of Research and Training (CIPE), A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil; Department of Head and Neck Surgery and Otorhinolaryngology, A. C. Camargo Cancer Center, Sao Paulo, SP 01.508-010, Brazil; Department of Urology, Faculty of Medicine, UNESP - Sao Paulo State University, Botucatu, SP 18.618-970, Brazil. Electronic address: silvia.rogatto@cipe.accamargo.org.br.
AC Camargo Hospital · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant association between DNA losses on 22q13.31 and head and neck squamous cell carcinomas (HNSCC) was previously reported by our group. Our data indicated that PHF21B gene, mapped on 22q13.31 and encoding a protein with function of chromatin-mediated transcriptional regulation, might be a putative tumor suppressor gene. To test this hypothesis, gene copy number was assessed in 75 HNSCC and 49 matched peripheral blood samples. PHF21B losses were detected in 43 tumors and were significantly associated with patients with familial history of cancer (P < 0.0001); i.e., 36/43 cases showed a positive family history of cancer and 22/36 had first-degree relatives with cancer (P = 0.049). In attempt to investigate other mechanisms for PHF21B loss of function, DNA sequencing was performed and no mutations were detected. We next evaluated the gene expression levels after inhibition of DNA methylation in nine HNSCC and breast carcinoma cell lines. Additionally, PHF21B expression levels were evaluated in colon cancer HCT116 cells as well as in its counterpart DKO (double knockout of DNMT1 and DNMT3B). The higher expression levels of PHF21B gene detected in DKO cells were inversely correlated with the DNA methylation. Further, DNA methylation in the specific promoter-associated CpG Island was investigated. Interestingly, gene hypermethylation was detected in 13/37 tumors: 5/13 HNSCC cases had family history of cancer in first-degree relatives and 8/13 showed both, DNA methylation and PHF21B losses in the tumor sample. One patient had PHF21B loss in the peripheral blood cells and PHF21B methylation in the tumor sample. Additionally, overexpression of PHF21B in cell lines drastically reduces clonogenic and migratory abilities. These data suggest that PHF21B is a novel tumor suppressor gene that can be inactivated by genetic and epigenetic mechanisms in the human cancer.

Indexed as

DNA MethylationAdultAgedAged, 80 and overCarcinoma, Squamous CellCell Line, TumorChromosomes, Human, Pair 22DNA, NeoplasmEpigenesis, GeneticFemaleGene Expression RegulationGene Knockdown TechniquesHead and Neck NeoplasmsHumansMaleMiddle AgedDNA, NeoplasmTumor Suppressor ProteinsCopy number alterationsEpigenetic changesHNSCCPHF21BTumor suppressor gene

Identifiers

PMID25454821
PMCPMC5528662
OpenAlexW2160953408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.